Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules
Jianjian Jin(National Institutes of Health Clinical Center), Steven L. Highfill(National Institutes of Health)
Cited by 54
Related Papers
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
|Journal of Clinical Oncology|2020|422
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells
|Blood|2021|194
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR
|Blood|2022|179
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
|Journal for ImmunoTherapy of Cancer|2022|59
CAR-T cell expansion platforms yield distinct T cell differentiation states
|Cytotherapy|2024|48